title: Lenvatinib receives approval in DTC.
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D018572:Disease-Free Survival; D017277:Drug Approval; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D011804:Quinolines / Q000009:adverse effects* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D010671:Phenylurea Compounds; D011804:Quinolines; C531958:lenvatinib